0
0
LONDON — In a landmark move to combat the growing obesity epidemic, the UK Government and pharmaceutical giant Eli Lilly and Company have announced a joint £85 million innovation program aimed at developing and testing new models of obesity care. The initiative is a direct response to the staggering economic cost of obesity, estimated at £74 billion annually to the UK economy.
The program, a collaboration with Innovate UK, is set to launch a nationwide competition inviting proposals from NHS organizations across England, Wales, Scotland, and Northern Ireland. The goal is to identify and pilot innovative approaches to obesity care that are both scalable and efficient, with a particular focus on modern and preventative solutions.
Funding for the ambitious project is a joint effort, with the Department for Science, Innovation and Technology (DSIT) contributing up to £50 million. Eli Lilly and Company will provide a substantial investment of up to £35 million, with a commitment of at least £10 million specifically allocated to projects in the devolved nations. A key aspect of the program is the explicit assurance that funding will not be used to influence prescribing decisions, maintaining the integrity of clinical judgment.
This initiative aligns with the government’s “Plan for Change” by championing an NHS focused on prevention and modern care delivery. Experts believe that new pathways for support, such as leveraging pharmacies and digital health tools, could significantly enhance the quality of life for those living with obesity. The evidence base generated from this program is expected to pave the way for a more effective and widespread support system throughout the UK.
Disclaimer: This news article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional for diagnosis and treatment of any health condition.
Reference:
Lilly and UK government launch £85 million obesity care innovation programme
